HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Incorporation of conserved nucleoprotein into influenza virus-like particles could provoke a broad protective immune response in BALB/c mice and chickens.

Abstract
We engineered influenza A/goose/GD/1996 (H5N1) (clade 0) virus-like particles (VLPs) by coinfecting Sf9 cells with triple/quadruple recombinant baculovirus that expressed hemagglutinin (HA), neuraminidase (NA), and matrix 1 (M1) with or without nucleoprotein (NP). VLP3 (HA, NA, and M1) and VLP4 (HA, NA, M1, and NP) vaccines (containing 1 μg HA) with oil emulsion were administered to mice and chickens by intramuscular injection, and the immune responses were analyzed. The VLP-vaccinated mice demonstrated high antigen specific antibody titers and effective cellular immune responses. The mice and chickens vaccinated with VLP4 demonstrated more robust humoral and cellular immune responses than those vaccinated with VLP3. The VLP4 vaccine afforded 100% protection against a heterologous lethal influenza virus challenge (clade 2.3.4) whereas the VLP3 vaccine conferred 50% protection in chickens. These results implied that the incorporation of conserved NP protein into the VLPs could elicit a broad protective immune response in BALB/c mice and chickens. To the best of our knowledge, this study is the first report describing the immunological profile of the NP-containing VLPs vaccines in mice and chicken models, and the results demonstrate that the non-infectious, genome less VLPs, particularly those containing NP, represent a promising strategy for the development of a safe and effective vaccine to control pandemic influenza.
AuthorsChunyi Xue, Guobin Tian, Xianxian Chen, Qiliang Liu, Jun Ma, Shun Xu, Xiaoming Li, Hualan Chen, Yongchang Cao
JournalVirus research (Virus Res) Vol. 195 Pg. 35-42 (Jan 02 2015) ISSN: 1872-7492 [Electronic] Netherlands
PMID25312452 (Publication Type: Journal Article)
Chemical References
  • Antibodies, Viral
  • Emulsions
  • Hemagglutinin Glycoproteins, Influenza Virus
  • Influenza Vaccines
  • M1 protein, Influenza A virus
  • NP protein, Influenza A virus
  • Nucleocapsid Proteins
  • RNA-Binding Proteins
  • Vaccines, Virus-Like Particle
  • Viral Core Proteins
  • Viral Matrix Proteins
  • Viral Proteins
  • NA protein, influenza A virus
  • Neuraminidase
Topics
  • Animals
  • Antibodies, Viral (blood)
  • Baculoviridae
  • Chickens
  • Cross Protection
  • Emulsions (administration & dosage)
  • Female
  • Genetic Vectors
  • Hemagglutinin Glycoproteins, Influenza Virus (genetics, immunology)
  • Influenza A Virus, H5N1 Subtype (genetics, immunology)
  • Influenza Vaccines (administration & dosage, genetics, immunology)
  • Influenza in Birds (prevention & control)
  • Injections, Intramuscular
  • Leukocytes, Mononuclear (immunology)
  • Mice, Inbred BALB C
  • Neuraminidase (genetics, immunology)
  • Nucleocapsid Proteins
  • Orthomyxoviridae Infections (prevention & control)
  • RNA-Binding Proteins (genetics, immunology)
  • Vaccination (methods)
  • Vaccines, Virus-Like Particle (administration & dosage, genetics, immunology)
  • Viral Core Proteins (genetics, immunology)
  • Viral Matrix Proteins (genetics, immunology)
  • Viral Proteins (genetics, immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: